A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.

I Ford
I Ford
Hammersmith and Queen Charlotte's Hospital
United Kingdom

Heart 2015 Feb 16;101(3):201-8. Epub 2014 Oct 16.

Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK.

Objectives: A policy model is a model that can evaluate the effectiveness and cost-effectiveness of interventions and inform policy decisions. In this study, we introduce a cardiovascular disease (CVD) policy model which can be used to model remaining life expectancy including a measure of socioeconomic deprivation as an independent risk factor for CVD.

Design: A state transition model was developed using the Scottish Heart Health Extended Cohort (SHHEC) linked to Scottish morbidity and death records. Individuals start in a CVD-free state and can transit to three CVD event states plus a non-CVD death state. Individuals who have a non-fatal first event are then followed up until death. Taking a competing risk approach, the cause-specific hazards of a first event are modelled using parametric survival analysis. Survival following a first non-fatal event is also modelled parametrically. We assessed discrimination, validation and calibration of our model.

Results: Our model achieved a good level of discrimination in each component (c-statistics for men (women)-non-fatal coronary heart disease (CHD): 0.70 (0.74), non-fatal cerebrovascular disease (CBVD): 0.73 (0.76), fatal CVD: 0.77 (0.80), fatal non-CVD: 0.74 (0.72), survival after non-fatal CHD: 0.68 (0.67) and survival after non-fatal CBVD: 0.65 (0.66)). In general, our model predictions were comparable with observed event rates for a Scottish randomised statin trial population which has an overlapping follow-up period with SHHEC. After applying a calibration factor, our predictions of life expectancy closely match those published in recent national life tables.

Conclusions: Our model can be used to estimate the impact of primary prevention interventions on life expectancy and can assess the impact of interventions on inequalities.
PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Source Status
http://dx.doi.org/10.1136/heartjnl-2014-305637DOI ListingPossible
February 2015
8 Reads

Similar Publications

A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities.

Open Heart 2016 10;3(1):e000140. Epub 2016 Jun 10.

Health Economics and Health Technology Assessment , Institute of Health & Wellbeing, University of Glasgow , Glasgow , UK.

Objectives: This is the second of the two papers introducing a cardiovascular disease (CVD) policy model. The first paper described the structure and statistical underpinning of the state-transition model, demonstrating how life expectancy estimates are generated for individuals defined by ASSIGN risk factors. This second paper describes how the model is prepared to undertake economic evaluation. Read More

View Article
June 2016

A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.

J Manag Care Pharm 2013 Mar;19(2):102-14

Department of Social, Behavioral, and Administrative Science, Touro University College of Pharmacy, 1310 Club Dr., Mare Island, Vallejo, CA 94592, USA.

Background: It has been demonstrated in previous studies that pharmacist management of patients with type 2 diabetes mellitus (T2DM) in the outpatient setting not only improves diabetes-related clinical outcomes such as hemoglobin A1c but also blood pressure (BP), total cholesterol (TC), and quality of life. Improved control of BP and TC has been shown to reduce the risks of cardiovascular disease (CVD), which has placed a heavy economic burden on the health care system. However, no study has evaluated the cost-effectiveness of pharmacist intervention programs with respect to the long-term preventive effects on CVD outcomes among T2DM patients. Read More

View Article
March 2013

A systematic review and economic evaluation of statins for the prevention of coronary events.

Health Technol Assess 2007 Apr;11(14):1-160, iii-iv

School of Health and Related Research (ScHARR), University of Sheffield, UK.

Objectives: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD).

Data Sources: Electronic databases were searched between November 2003 and April 2004.

Review Methods: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. Read More

View Article
April 2007

Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.

PLoS Med 2012 27;9(12):e1001361. Epub 2012 Dec 27.

Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.

Background: Physicians need to inform asymptomatic individuals about personalized outcomes of statin therapy for primary prevention of cardiovascular disease (CVD). However, current prediction models focus on short-term outcomes and ignore the competing risk of death due to other causes. We aimed to predict the potential lifetime benefits with statin therapy, taking into account competing risks. Read More

View Article
June 2013